{
    "Does psilocybin cause psychosis?": {
        "v1": "Psilocybin can induce psychosis-like symptoms in some individuals, but it is not known to cause long-term psychosis. The mechanisms responsible for the therapeutic effects and side effects of psilocybin are still being studied.",
        "v2": {
            "output_text": "Psilocybin has the potential to cause psychosis, but there is no clear evidence that it does. One study documented the development of substance-induced psychosis in a patient who used a large amount of psilocybin, but other studies did not find significant associations between psilocybin use and mental health outcomes. Psilocybin has been shown to produce a \"model psychosis\" resembling some symptoms of schizophrenia. However, it is not clear whether psilocybin causes psychosis in the same way as schizophrenia. Further research is needed to determine the relationship between psilocybin and psychosis. \nSOURCES: 36049313, 36048112, 35900779, 23976938, 23942028, 23784738, 22030715"
        },
        "v3": {
            "output_text": "\n\nThe existing answer remains accurate and relevant to the question. However, it is important to note that psilocybin and other serotonergic hallucinogens can produce a \"model psychosis\" in normal individuals that resembles some of the positive symptoms of schizophrenia. The study mentioned in the new context suggests that psilocybin does not disrupt prediction error processing, which is implicated in the formation of cognitive impairments in schizophrenia. While clinical studies do not suggest that psychedelics cause long-term mental health problems, the use of psilocybin and other hallucinogens can lead to the development of hyperactive syndromes, including substance-induced psychosis. It is crucial for physicians to be vigilant in monitoring patients who use psilocybin and other hallucinogens to prevent life-threatening hyperactive syndromes. Additionally, the use of these substances can lead to hallucinogen persisting perception disorder (HPPD), which can cause visual disturbances that resemble psychedelic intoxication and persist after use has ceased. It is important to distinguish between HPPD and typical psychotic presentations in order to provide proper treatment. Benzodiazepines may be used to treat HPPD, but the risks and benefits of long-term use must be weighed.\n\nSources: \n- 237847"
        },
        "v4": "Psilocybin has been shown to produce temporary psychosis-like effects in some people, but it is not generally considered to cause long-term psychosis. However, it may worsen symptoms in people who already have a psychotic disorder.",
        "v5": {
            "output_text": "Psilocybin may induce a psychosis-like head-twitch response, but there is no evidence that it causes psychosis. However, psychotomimetics like psilocybin may induce psychotic symptoms that resemble those of schizophrenia. Some studies even suggest that psychedelic use may be associated with a lower rate of mental health problems. \nSOURCES: 36049313, 36048112, 35900779, 23976938, 23942028, 23784738, 22030715."
        },
        "v6": {
            "output_text": "\n\nThe new context is discussing the effects of psilocybin and ketamine on the processing of prediction errors in healthy subjects and their correlation with drug-induced symptoms, but it does not directly address whether psilocybin causes psychosis. Therefore, the original answer remains unchanged:\n\nBased on the available evidence, psilocybin is not known to cause long-term mental health problems or addiction. While there have been rare cases of substance-induced psychosis associated with high doses of psilocybin, there is no clear evidence that psilocybin causes psychosis in the general population. Animal models relevant to schizophrenia have been developed based on hallucinogen effects, which have yielded important insights into the linkage between 5-HT and schizophrenia. However, it is important to note that these models are based on the use of high doses of serotonergic hallucinogens such as psilocybin and may not accurately represent the effects of therapeutic doses used in humans. Overall, while individual cases of adverse effects may occur, psilocybin therapy may be a safe and effective treatment for certain conditions when properly monitored by a physician. (Sources: 36048112, 35900779, 23976938, 23942028)"
        }
    },
    "What are some non\u2010pharmacological interventions for headache in children and adolescents?": {
        "v1": "Non-pharmacological interventions for headache in children and adolescents include repetitive neuromuscular magnetic stimulation (rNMS), cognitive behavioral therapy (CBT), transcendental meditation (TM), hypnotherapy (HT), and progressive muscle relaxation (PMR) exercises. These interventions have been shown to reduce headache frequency and related disability in youth with headache and migraine and have a favorable benefit to risk profile with almost no negative side effects. However, larger, prospective, randomized, sham-controlled studies are urgently needed to confirm their effectiveness.",
        "v2": {
            "output_text": "Non-pharmacological interventions for headache in children and adolescents include rest, exercise, vestibular therapy, cervical spine exercises, cognitive behavioral therapy (CBT), transcendental meditation, hypnotherapy, and progressive muscle relaxation exercises. Remote electrical neuromodulation (REN) may also be a safe and effective non-pharmacological alternative for acute treatment in adolescents with migraine. However, the given portion of the document does not provide specific information on non-pharmacological interventions for headache in children and adolescents. \nSOURCES: 30444269, 31025612, 31317889, 33349920, 34153363, 35120753, 35660103, 30357468."
        },
        "v3": {
            "output_text": "\n\nRefined answer: Non-pharmacological interventions for headache in children and adolescents include cognitive-behavioral therapy (CBT), relaxation techniques such as transcendental meditation (TM), hypnotherapy (HT), and progressive muscle relaxation (PMR), biofeedback, and acupuncture. CBT has been repeatedly demonstrated as effective in treating pediatric headache and migraine and should be considered as part of first-line preventive treatment for pediatric headache (either alone or in combination with a pill-based therapy). TM, HT, and PMR have also been shown to be effective in reducing primary headaches in children and adolescents. No significant differences were found between the three techniques, suggesting that children can choose either one of the three techniques based on personal preferences. However, the effectiveness of these interventions specifically for pediatric mild traumatic brain injury (mTBI)-related headaches is unknown. Rest, exercise, vestibular therapy, and cervical spine exercises are commonly recommended by practitioners who care for children with pediatric mTBI-related headaches. Emotional and behavioral disorders may affect the clinical features and duration of headaches in children and adolescents with frequent episodic or chronic tension-type headaches (TTH) after mTBI. Further research is needed to determine the effectiveness of non-pharmacological interventions for pediatric mTBI-related headaches."
        },
        "v4": "There are several non-pharmacological interventions for headache in children and adolescents, including repetitive neuromuscular magnetic stimulation (rNMS), cognitive behavioral therapy (CBT), mind-body techniques like transcendental meditation and hypnotherapy, and various behavioral strategies like bedtime fading, gradual extinction, and positive reinforcement of adapted behaviors. These interventions have been shown to reduce headache frequency and intensity, improve functional ability, and have a favorable benefit-to-risk profile with almost no negative side effects. However, larger, prospective, randomized, and controlled studies are needed to confirm their effectiveness and to develop efficient approaches for integrating these interventions into headache specialty, neurology, and primary care settings.",
        "v5": {
            "output_text": "Non-pharmacological interventions for headache in children and adolescents include rest, exercise, vestibular therapy, cervical spine exercises, and non-invasive treatments like remote electrical neuromodulation (REN), transcendental meditation, hypnotherapy, and progressive muscle relaxation exercises. Cognitive behavioral therapy (CBT) has also been shown to decrease headache frequency and related disability in youth with headaches and migraines. Specific non-pharmacological interventions for headaches in children and adolescents are not provided in some of the sources. \nSOURCES: 31025612, 33349920, 30357468, 30444269, 34153363, 35660103, 35120753, 31317889."
        },
        "v6": {
            "output_text": "\n\nThe refined answer is: In addition to cognitive-behavioral therapy (CBT), non-pharmacological interventions for headaches in children and adolescents include relaxation techniques such as transcendental meditation, hypnotherapy, and progressive muscle relaxation exercises. A study found that all three techniques reduce primary headache in children and appear to be safe. Clinically relevant headache reduction (>/= 50%) was observed in 41% and 47% of children at 3 and 9 months respectively, with no significant differences between the groups. However, further research is needed to determine which technique is most effective for individual patients. It is important to consider the severity of co-morbid emotional and behavioral disorders when determining individualized non-pharmacological treatment approaches for pediatric tension-type headaches. Further research is also needed to better understand how these techniques work and to develop effective approaches for integrating them into headache specialty, neurology, and primary care settings.\n\nSources:\n- https://www.ncbi.nlm.nih.gov/pubmed/30444269\n- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114164/\n- https://pubmed.ncbi.nlm.nih.gov/31317889/\n- https://pubmed.ncbi.nlm.nih.gov/31025612/\n- https://www.ncbi.nlm"
        }
    },
    "What are the indications for spontaneous bacterial peritonitis prophylaxis?": {
        "v1": "The indications for spontaneous bacterial peritonitis prophylaxis include patients at risk for a first episode of SBP due to a low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP, and those with an episode of gastrointestinal bleeding.",
        "v2": {
            "output_text": "The indications for spontaneous bacterial peritonitis prophylaxis include: patients at risk for a first episode of SBP due to a low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP, and those with an episode of gastrointestinal bleeding. Rifaximin is also indicated for SBP prophylaxis. However, there is no information on the indications for SBP prophylaxis in the given portion of the document. \nSOURCES: 30631393, 31855490, 31228250, 33321078, 34653572, 36820931"
        },
        "v3": {
            "output_text": "\n\nThe original answer remains relevant and accurate, as the study cited did not provide specific indications for spontaneous bacterial peritonitis (SBP) prophylaxis. However, the new context provides additional information on the standard indications for SBP prophylaxis, which include patients at risk for a first episode of SBP due to a low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP, and those with an episode of gastrointestinal bleeding. It also highlights the potential negative consequences of extended use of antibiotics in patients with cirrhosis, including the emergence of multi-drug resistant bacteria. \n\nSources: 31228250, 30631393"
        },
        "v4": "Indications for spontaneous bacterial peritonitis prophylaxis include patients at risk for a first episode of SBP due to low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP, and patients with an episode of gastrointestinal bleeding.",
        "v5": {
            "output_text": "The indications for spontaneous bacterial peritonitis prophylaxis include patients at risk for a first episode of SBP due to a low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP and those with an episode of gastrointestinal bleeding. \nSOURCES: 30631393"
        },
        "v6": {
            "output_text": "\n\nThe indications for spontaneous bacterial peritonitis (SBP) prophylaxis include patients at risk for a first episode of SBP due to a low ascitic fluid protein count and impaired liver and kidney function, as well as those with a prior episode of SBP and those with an episode of gastrointestinal bleeding. However, prophylaxis due to gastrointestinal bleeding has a known and short duration. Patients with cirrhosis who have these risk factors are at a higher risk of bacterial infections, which can lead to hospitalization and short-term mortality. Antibiotic prophylaxis has been the standard of care for decades in high-risk subgroups of patients with cirrhosis to reduce bacterial infection episodes and mortality, but extended use of antibiotics has also led to the emergence of multi-drug resistant bacteria. There are currently no standardized criteria for re-assessing antibiotic interruption, and the preferred prophylaxis strategy for patients with cirrhosis in the future is still unclear. \nSource: 30631393"
        }
    },
    "What are the reasons to start antibiotics to prevent spontaneous bacterial peritonitis prophylaxis?": {
        "v1": "The reasons to start antibiotics to prevent spontaneous bacterial peritonitis prophylaxis are to provide appropriate acute management and to prevent recurrence in the long term. Patients with cystic fibrosis liver disease should receive immediate paracentesis for any evidence of recurrence. It is recommended to use a wide spectrum antimicrobial agent with activity against Pseudomonas aeruginosa, other common Gram negative organisms, and Staphylococcus aureus.",
        "v2": {
            "output_text": "The given content does not provide information about the reasons to start antibiotics to prevent spontaneous bacterial peritonitis prophylaxis.\nSOURCES:"
        },
        "v3": {
            "output_text": "The reasons to start antibiotics to prevent spontaneous bacterial peritonitis prophylaxis are to provide appropriate acute management, including antimicrobial treatment, and to use a wide spectrum antimicrobial agent with activity against Pseudomonas aeruginosa, other common Gram negative organisms, and Staphylococcus aureus. This is recommended for patients with cystic fibrosis who are at risk for spontaneous bacterial peritonitis."
        },
        "v4": "The reasons to start antibiotics for spontaneous bacterial peritonitis prophylaxis are to manage the potential recurrence of the condition and to provide acute management, including antimicrobial treatment. It is also important to use a wide spectrum antimicrobial agent with activity against Pseudomonas aeruginosa, other common Gram-negative organisms, and Staphylococcus aureus.",
        "v5": {
            "output_text": "The content only mentions the use of antimicrobial agents, but does not provide specific reasons for starting antibiotics to prevent spontaneous bacterial peritonitis prophylaxis. \nSOURCES: 8200573"
        },
        "v6": {
            "output_text": "The reasons to start antibiotics to prevent spontaneous bacterial peritonitis prophylaxis are not explicitly stated in the context information. However, it is recommended to use a wide spectrum antimicrobial agent with activity against Pseudomonas aeruginosa, other common Gram negative organisms, and Staphylococcus aureus in patients with cystic fibrosis who are at risk for spontaneous bacterial peritonitis. This can be given either as chronic (continuous) antimicrobial prophylaxis or only during periods when bacteraemia is possible (such as dental work or bronchoscopy). Early diagnostic paracentesis is also essential for appropriate acute management."
        }
    }
}
